Globus Medical Q4 sales $657.3M (+6.6% YoY); guides 2025 with Nevro acquisition impact

GLOBUS MEDICAL INC

2024-FY EPS reported $0.75 revenue$2,519,355,000

Q4 net sales $657.3M (+6.6% as-reported, +6.9% constant currency); GAAP EPS $0.19, non-GAAP EPS $0.84.
Full-year 2024 net sales $2,519.4M (+60.6% YoY); GAAP net income $103.0M; GAAP EPS $0.75, non-GAAP EPS $3.04.
2025 stand-alone guidance: revenue $2.66-2.69B, non-GAAP EPS $3.40-3.50; with Nevro acquisition (close late Q2): revenue $2.80-2.90B, non-GAAP EPS $3.10-3.40.
Q4 non-GAAP adjusted EBITDA $196.9M (30.0% of sales); full-year operating cash flow $520.6M, free cash flow $405.2M.
CEO cites record product launches and integration progress; team executed on strategic objectives to drive value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.